Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
Titel:
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
Auteur:
Delforge, Michel Otero, Paula RodrÃguez Shah, Nina Moshkovich, Olga Braverman, Julia Dhanda, Devender S. Lanar, Sally Devlen, Jennifer Miera, Matthew Gerould, Heather Campbell, Timothy B. Munshi, Nikhil C.